Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOTHAM trial of gemtuzumab ozogamicin for relapsed/refractory HLH, MAS, or solid tumors
ISRCTN89158144Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of gemtuzumab ozogamicin in haemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS) and Nonhematologic neoplasms (2 arms), sponsored by University of Birmingham. Started Jun 2021; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)macrophage activation syndrome (MAS)Nonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN89158144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89158144.